Fore Pharmas latest report ‘Global Pneumococcal Infections Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global pneumococcal infections drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the pneumococcal infections drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Pneumococcal Infections: Overview
- Pneumococcal Infections Drug Pipeline Overview
- Pneumococcal Infections Phase 3 Clinical Trial Drug Pipeline Insights
- Pneumococcal Infections Phase 2 Clinical Trial Drug Pipeline Insights
- Pneumococcal Infections Phase 1 Clinical Trial Drug Pipeline Insights
- Pneumococcal Infections Preclinical Research Drug Pipeline Insights
- Pneumococcal Infections Drug Discovery Pipeline Insights
- Geographic Landscape of Pneumococcal Infections R&D Activities
- Pneumococcal Infections R&D Activities in North America
- Pneumococcal Infections R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Pneumococcal Infections Drug Market
 

1. Pneumococcal Infections: Disease Definition
2. Pneumococcal Infections Drug Pipeline Overview
3. Pneumococcal Infections Phase 3 Clinical Trial Drug Pipeline Insights
4. Pneumococcal Infections Phase 2 Clinical Trial Drug Pipeline Insights
5. Pneumococcal Infections Phase 1 Clinical Trial Drug Pipeline Insights
6. Pneumococcal Infections Preclinical Research Drug Pipeline Insights
7. Pneumococcal Infections Drug Discovery Pipeline Insights
8. Geographic Landscape of Pneumococcal Infections R&D Activities
8.1 Pneumococcal Infections R&D Activities in North America
8.2 Pneumococcal Infections R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Pneumococcal Infections Drug Market
10 Research Methodology

List of Tables

Table 1: Pneumococcal Infections Drug Pipeline: Phase 3 Clinical Trial
Table 2: Pneumococcal Infections Drug Pipeline: Phase 2 Clinical Trial
Table 3: Pneumococcal Infections Drug Pipeline: Phase 1 Molecules
Table 4: Pneumococcal Infections Drug Pipeline: Preclinical Research
Table 5: Pneumococcal Infections R&D Activities by Geography
Table 6: Pneumococcal Infections Drug Pipeline: North America
Table 7: Pneumococcal Infections Drug Pipeline: Europe
Table 8: Pneumococcal Infections Drug Pipeline: Licensing Activities

List of Figures

Figure 1 : Pneumococcal Infections Drug Pipeline Molecules by Stages
Figure 2 : Pneumococcal Infections R&D Activities by Geography